TRANEXAMIC ACID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H15NO2
Molecular Weight	157.2102
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC[C@H]1CC[C@@H](CC1)C(O)=O

InChI

InChIKey=GYDJEQRTZSCIOI-LJGSYFOKSA-N

InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00302
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf

Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1). Tranexamic acid is used for use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
fibrinolysis 3 Target ID: GO:0042730 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8731512	Inhibitor 8146		60.0 µM [IC50]
Plasminogen 6 Target ID: CHEMBL1801 Sources: http://www.drugbank.ca/drugs/DB00302 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Inhibitor 8146		3.1 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cyclic heavy menstrual bleeding 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Primary		Approved 8307	LYSTEDA Approved Use LYSTEDA (tranexamic acid) Tablets is an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding. Launch Date 5.36198414E11

C_max

Value	Dose	Co-administered	Analyte	Population
16.41 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg 3 times / day multiple, oral dose: 1300 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
13.83 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg single, oral dose: 1300 mg route of administration: Oral experiment type: SINGLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
77.67 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg 3 times / day multiple, oral dose: 1300 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
80.19 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg single, oral dose: 1300 mg route of administration: Oral experiment type: SINGLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.08 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg single, oral dose: 1300 mg route of administration: Oral experiment type: SINGLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
97% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	1300 mg single, oral dose: 1300 mg route of administration: Oral experiment type: SINGLE co-administered:		TRANEXAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Other AEs: Headache, Nasal disorder NOS... Other AEs: Headache (50.4%) Nasal disorder NOS (25.4%) Back pain (20.7%) Abdominal pain (19.8%) Musculoskeletal pain (11.2%) Arthralgia (6.9%) Muscle cramps (6.5%) Migraine (6%) Anemia (5.6%) Fatigue (5.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
1 g 4 times / day steady, oral Overdose Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/	unhealthy, 45 years n = 1 Health Status: unhealthy Condition: chronic kidney disease Age Group: 45 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/	Disc. AE: Convulsions generalized... AEs leading to discontinuation/dose reduction: Convulsions generalized (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/
2000 mg 1 times / day steady, intravenous Recommended Dose: 2000 mg, 1 times / day Route: intravenous Route: steady Dose: 2000 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/	unhealthy, 56 years n = 1 Health Status: unhealthy Condition: emergency operation for a bleeding ulcer of the stomach and duodenum Age Group: 56 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/	Disc. AE: Blindness... AEs leading to discontinuation/dose reduction: Blindness (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/
250 mg 2 times / day steady, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: steady Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/	unhealthy, mean 40.7 years n = 561 Health Status: unhealthy Condition: Melasma Age Group: mean 40.7 years Sex: M+F Population Size: 561 Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/	Disc. AE: Deep vein thrombosis leg... AEs leading to discontinuation/dose reduction: Deep vein thrombosis leg (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/

AEs

AE	Significance	Dose	Population
Musculoskeletal pain	11.2%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Abdominal pain	19.8%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Back pain	20.7%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Nasal disorder NOS	25.4%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Fatigue	5.2%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Anemia	5.6%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Headache	50.4%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Migraine	6%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Muscle cramps	6.5%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Arthralgia	6.9%	1300 mg 3 times / day steady, oral Recommended Dose: 1300 mg, 3 times / day Route: oral Route: steady Dose: 1300 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	healthy, 18 - 49 years n = 232 Health Status: healthy Condition: cyclic heavy menstrual bleeding Age Group: 18 - 49 years Sex: F Population Size: 232 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf
Convulsions generalized	1 patient Disc. AE	1 g 4 times / day steady, oral Overdose Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/	unhealthy, 45 years n = 1 Health Status: unhealthy Condition: chronic kidney disease Age Group: 45 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/24434397/
Blindness	1 patient Disc. AE	2000 mg 1 times / day steady, intravenous Recommended Dose: 2000 mg, 1 times / day Route: intravenous Route: steady Dose: 2000 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/	unhealthy, 56 years n = 1 Health Status: unhealthy Condition: emergency operation for a bleeding ulcer of the stomach and duodenum Age Group: 56 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/14712363/
Deep vein thrombosis leg	1 patient Disc. AE	250 mg 2 times / day steady, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: steady Dose: 250 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/	unhealthy, mean 40.7 years n = 561 Health Status: unhealthy Condition: Melasma Age Group: mean 40.7 years Sex: M+F Population Size: 561 Sources: https://pubmed.ncbi.nlm.nih.gov/27206758/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1532	inhibitor 1695	inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2A6 670 CYP2C19 1410 CYP2E1 846 OATP1B1 770 OATP1B3 691

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1620	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 702	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 1747	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMODc3In19	no [IC50 >10 uM]
CYP2E1 929	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDg3NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP3A4 1857	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMODc3In19	no [IC50 >10 uM]
OATP1B1 785	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OATP1B3 700	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMODc3In19

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:48669	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:48669
ChemicalBook	CB1117189	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1117189
ChemicalBook	CB2948513	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2948513
ChemicalBook	CB54848494	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB54848494
MolPort	MolPort-002-512-008	https://www.molport.com/shop/molecule-link/MolPort-002-512-008
Selleck Chemicals	tranexamic-acid-transamin	http://www.selleckchem.com/products/tranexamic-acid-transamin.html
ZINC	ZINC000100071256	http://zinc15.docking.org/substances/ZINC000100071256
eMolecules	476513	https://www.emolecules.com/cgi-bin/more?vid=476513

PubMed

Title	Date	PubMed
The epileptogenic effect of tranexamic acid.	1999 Sep	10525986
Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model.	2000 Dec	11126922
The emerging periplasm-localized subclass of AroQ chorismate mutases, exemplified by those from Salmonella typhimurium and Pseudomonas aeruginosa.	2001	11532214
A new vascular sealant (Sealgel) to achieve rapid hemostasis after percutaneous angioplasty in anticoagulated patients: clinical feasibility and preliminary results.	2001	11288852
Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.	2001 Apr	11279640
Therapies for the treatment of abnormal uterine bleeding.	2001 Dec	12112970
Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding.	2001 Dec	11829234
Prevention of the adverse effects of aprotinin in autologous fibrin glue.	2001 Jan	11201238
Congenital alpha(2)-plasmin inhibitor deficiencies: a review.	2001 Jul	11472338
Tranexamic acid in aortic valve replacement.	2001 Jun	11426364
Re: Webster K, Wilde J. Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations. Br J Oral Maxillofac Surg 2000; 38: 124-126.	2001 Jun	11384128
Plasminogen binding is increased with adipocyte differentiation.	2001 Jun 8	11394891
Binding diversity of a noncovalent-type low-molecular-weight serine protease inhibitor and function of a catalytic water molecule: X-ray crystal structure of PKSI-527--inhibited trypsin.	2001 Mar	11226886
Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia.	2001 Mar 12	11231712
Successful arthroscopic treatment of pigmented villonodular synovitis of the knee in a patient with congenital deficiency of plasminogen activator inhibitor-1 and recurrent haemarthrosis.	2001 Mar-Apr	11684866
Enhanced thrombolysis induced by argatroban or activated protein C in the presence or absence of staphylokinase, measured in an in vivo animal model using mesenteric arterioles.	2001 Mar-Apr	11684863
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.	2001 May	11422178
Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery.	2001 Sep	11573859
Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.	2001 Sep	11511559
Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia.	2001 Sep 20	11565536
Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery.	2002	12381219
Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.	2002	12214734
Danazol for heavy menstrual bleeding.	2002	12076401
Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time.	2002 Apr	11943936
Pharmacokinetics of tranexamic acid during cardiopulmonary bypass.	2002 Aug	12151929
Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.	2002 Jan	11807648
Purification and characterization of a novel esterase promising for the production of useful compounds from Microbacterium sp. 7-1W.	2002 Jan 10	11814667
Oral surgery in patients undergoing oral anticoagulant therapy.	2002 Jan-Feb	11788810
[Pulmonary embolism (PE) associated with urological surgery and angiography].	2002 Jul	12174640
[Contribution of Japanese researchers to progress in the field of hematology in the last 100 years: Congenital deficiency of alpha2-plasmin inhibitor].	2002 Jul 10	12187678
Rendu-Osler-Weber disease: experience with 56 patients.	2002 Jul-Sep	12402665
Menorrhagia.	2002 Jun	12230783
Clinical management of hereditary angio-oedema in children.	2002 Jun	12144636
Hemostatic effects of tranexamic acid in elective thoracic aortic surgery: a prospective, randomized, double-blind, placebo-controlled study.	2002 Jun	12063454
Re: Webster K, Wilde J. Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations. Br J Oral Maxillofac Surg 2000; 38: 124-126.	2002 Jun	12054729
Acute myocardial infarction after oral tranexamic acid treatment initiation.	2002 Jun	12036532
Acquired factor VIII inhibitors as a cause of primary post-partum haemorrhage.	2002 Jun 10	12039476
[Continuous infusion of recombinant activated factor VII during and after elbow arthroplasty in a hemophilia A patient with inhibitors].	2002 Mar	11979750
Development of novel topical tranexamic acid liposome formulations.	2002 Mar 20	11879740
Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group.	2002 May 20	11992774
[Familial study of factor XI deficiency. Presurgical prophylactic treatment with desmopressin plus antifibrinolytics].	2002 Oct	12392675
Impact of hematocrit value after coronary artery surgery on perioperative myocardial infarction rate.	2002 Oct	12375180
Mast cell-derived VEGF enhances the passage of IgE FE-3 through the rat aortic endothelial cell monolayer.	2002 Sep	12373001
A comparison of clinical assessment with ultrasound in the management of secondary postpartum haemorrhage.	2002 Sep 10	12206921
Effect of fibrin sealant composition on human neutrophil chemotaxis.	2002 Sep 5	12115473
Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature.	2002 Sep-Oct	12237729

Patents

Sample Use Guides

In Vivo Use Guide

1,300 mg (two 650 mg tablets) three times a day (3,900 mg/day) for a maximum of 5 days during monthly menstruation

Route of Administration: Oral

In Vitro Use Guide

0.03 mg/mL Tranexamic acid reduced the fibrinogen fall induced by t-PA 20 nM from 43% to 14%.

Name

Type

Language

TRANEXAMIC ACID

Official Name

English

TRANEXAMIC ACID [USP MONOGRAPH]

Common Name

English

TRANEXAMIC ACID [USP-RS]

Common Name

English

TRANS-4-(AMINOMETHYL)CYCLOHEXANECARBOXYLIC ACID

Systematic Name

English

CYCLOHEXANECARBOXYLIC ACID, 4-(AMINOMETHYL)-, TRANS-

Systematic Name

English

CYCLO-F

Brand Name

English

tranexamic acid [INN]

Common Name

English

RP-18429

Code

English

AMCHA

Common Name

English

TRANEXAMIC ACID [USAN]

Common Name

English

TRANSAMIN

Brand Name

English

LYSTEDA

Brand Name

English

NSC-291305

Code

English

TRANEXAMIC ACID [USP IMPURITY]

Common Name

English

TRANEXAMIC ACID [ORANGE BOOK]

Common Name

English

HAEMATRIX

Brand Name

English

CYCLOCAPRON

Common Name

English

CL 65336

Code

English

TRANEXAMIC ACID [MART.]

Common Name

English

CL-65336

Code

English

CYKLOKAPRON

Brand Name

English

TRANS-AMCHA

Code

English

TRANEXAMIC ACID [INCI]

Common Name

English

ESPERCIL

Brand Name

English

TRANEXAMIC ACID [VANDF]

Common Name

English

TRANEXAMIC ACID [EP MONOGRAPH]

Common Name

English

TRANEXAMIC ACID [JAN]

Common Name

English

LB1148

Code

English

CYCLOKAPRON

Common Name

English

Tranexamic acid [WHO-DD]

Common Name

English

TRANEXAMIC ACID [MI]

Common Name

English

FEMSTRUAL

Brand Name

English

TRANS AMCHA

Code

English

RIKAVARIN

Brand Name

English

Classification Tree Code System Code

LIVERTOX

988